Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Angiog...

    2026-03-30

    SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Angiogenesis and Immune Modulation Research

    Executive Summary: SU5416 (Semaxanib) is a highly selective small molecule inhibitor of VEGFR2 (Flk-1/KDR) with an IC50 of 1.23 μM, showing over 1000-fold selectivity for VEGF-mediated versus FGF-mediated mitogenesis (APExBIO). It potently inhibits VEGF-induced angiogenesis and endothelial cell proliferation, leading to significant suppression of tumor vascularization in vivo (Xiao et al., 2024). SU5416 also acts as an aryl hydrocarbon receptor (AHR) agonist, modulating immune responses through IDO induction and regulatory T cell differentiation. Its efficacy is verified in HUVEC cell lines and murine xenograft models, with established dosing and solubility parameters. The compound is for research use only and must not be used for diagnostic or therapeutic purposes.

    Biological Rationale

    Angiogenesis is crucial for tumor growth, wound healing, and various pathological conditions such as cancer and pulmonary arterial hypertension. The vascular endothelial growth factor (VEGF) pathway, especially via VEGFR2 (also known as Flk-1/KDR), regulates endothelial cell proliferation, migration, and new vessel formation (Xiao et al., 2024). Hypoxia-inducible factor 1α (HIF1α) upregulates VEGF expression under low oxygen, further promoting angiogenesis and metabolic adaptation in tumors. Therefore, inhibition of the VEGFR2 signaling axis is a validated strategy for suppressing angiogenesis and tumor vascularization. SU5416 (Semaxanib), as formulated and distributed by APExBIO, is designed to enable precise dissection of these pathways in preclinical models (product page).

    Mechanism of Action of SU5416 (Semaxanib)

    • SU5416 selectively inhibits VEGFR2 (Flk-1/KDR) tyrosine kinase activity. It blocks VEGF-induced autophosphorylation and downstream signaling in endothelial cells (APExBIO).
    • The compound has an IC50 of 1.23 μM for VEGFR2, with >1000-fold selectivity against FGF-driven mitogenesis, indicating high pathway specificity.
    • By inhibiting VEGFR2, SU5416 prevents endothelial cell proliferation and tube formation, thereby restricting new vessel formation in tumors and pathological tissues.
    • SU5416 also functions as an aryl hydrocarbon receptor (AHR) agonist, leading to upregulation of indoleamine 2,3-dioxygenase (IDO) and increased regulatory T cell (Treg) differentiation, which impacts immune tolerance (Xiao et al., 2024).

    Evidence & Benchmarks

    • SU5416 exhibits an IC50 of 1.23 μM for VEGFR2 kinase inhibition in in vitro kinase assays (APExBIO).
    • It demonstrates >1000-fold selectivity for VEGF-driven mitogenesis over FGF-driven mitogenesis in cell-based assays (APExBIO).
    • In HUVECs, SU5416 blocks VEGF-induced endothelial cell proliferation at concentrations as low as 0.01 μM, with maximal inhibition near 10 μM (APExBIO).
    • In mouse xenograft models, daily dosing at 3–25 mg/kg significantly reduces tumor vascularization without observed mortality (APExBIO).
    • SU5416 acts as an AHR agonist, leading to IDO induction and promoting Treg differentiation, thereby modulating immune responses relevant to cancer and transplant tolerance (Xiao et al., 2024).
    • The compound is insoluble in ethanol and water but soluble in DMSO at concentrations ≥11.9 mg/mL; stock solutions are stable below −20°C (APExBIO).

    For a broader review of advanced VEGFR2 inhibition, see this article; the present piece extends the focus to immune modulation and practical workflow guidance.

    Applications, Limits & Misconceptions

    SU5416 is validated for research in cancer angiogenesis, immune modulation, and models of pulmonary vascular disease. It is employed in studies dissecting the VEGF/VEGFR2 axis, tumor microenvironment, and immune tolerance mechanisms. The robust selectivity profile supports its use in distinguishing VEGF-driven versus non-VEGF vascular responses. Additionally, as an AHR agonist, SU5416 enables investigation into IDO-mediated pathways and regulatory T cell biology. Research using SU5416 has clarified the metabolic interplay between angiogenesis and immune regulation, as described in this related review; this article updates benchmarks and workflow integration.

    Common Pitfalls or Misconceptions

    • SU5416 is not suitable for diagnostic or clinical therapeutic use; it is for research purposes only (APExBIO).
    • The compound is insoluble in aqueous or ethanol solvents; DMSO is required for stock preparation.
    • Degradation may occur if solutions are not stored below −20°C or are exposed to light for extended periods.
    • SU5416 does not inhibit FGF-driven or non-VEGF-dependent angiogenesis at relevant concentrations.
    • It may not be effective in cell types lacking VEGFR2 expression or in angiogenesis-independent tumor growth models.

    Workflow Integration & Parameters

    For in vitro studies, prepare SU5416 stock solutions in DMSO at ≥11.9 mg/mL. Working concentrations typically range from 0.01 to 100 μM, depending on cell type and endpoint. For endothelial cell assays (e.g., HUVEC proliferation), effective inhibition is observed from 0.01 μM upward. In vivo, administer SU5416 by intraperitoneal or intravenous injection at 3–25 mg/kg/day in murine xenograft models, monitoring for toxicity and efficacy.

    Stock solutions should be aliquoted and stored in the dark at −20°C; avoid repeated freeze-thaw cycles. The product’s chemical identity is (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one (C15H14N2O, 238.28 g/mol). For expanded applications, see this recent overview; this article clarifies dosing and handling for robust experimental reproducibility.

    Conclusion & Outlook

    SU5416 (Semaxanib) is a well-characterized, highly selective VEGFR2 inhibitor with dual anti-angiogenic and immune modulatory functions. Its robust selectivity, defined solubility, and validated in vitro/in vivo benchmarks make it a cornerstone compound for dissecting VEGF signaling and immune regulation in cancer, vascular, and autoimmune research. As new data on metabolic and immune crosstalk (e.g., HIF1α, IDO) emerge, SU5416’s utility in mechanistic and translational studies will likely expand. For product specifications and ordering, see the official APExBIO SU5416 (Semaxanib) page.